What is it about?
A current view on why biomarkers fail in the clinic. Of course there are many reasons, but here the emphasis is put on the pivotal role antibodies play for the identification of protein biomarkers. Controversy over the integrity of commercial antibodies can be overcome when they are properly characterized and properly reported in publications.
Featured Image
Why is it important?
The dogma that monoclonal antibodies are the only reliable ones has caused lots of frustration among the commercial assay developers. Many simply do not work. It is important to realize that the requirements of consistency between purchases and mono-specificity can also be achieved when working with peptide-generated polyclonal antibodies. One prerequisite is that the immunizing peptide is chosen wisely.
Perspectives
This is an interview to introduce myself to the world of research antibodies and the world of assay developers for laboratory developed tests and for companion diagnostics.
Dr Jan LA Voskuil
Aeonian Biotech
Read the Original
This page is a summary of: Biomarkers and their dependence on well-reported antibodies, Personalized Medicine, November 2015, Future Medicine,
DOI: 10.2217/pme.15.24.
You can read the full text:
Contributors
The following have contributed to this page
